ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DRIO
BEAT (42) PLRZ (34) NEPH (59) TELA (35) ⌘ Pro Terminal →

DarioHealth Corp. (DRIO) — RQD Stock Rating Cockpit

$3.03 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.03

DarioHealth Corp. (DRIO) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $29.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DRIO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, DarioHealth Corp. (NASDAQ: DRIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.03 (+1.00% 1D, market cap $29.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, DRIO ranks #694 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DRIO compare to BEAT and PLRZ in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M) and PLRZ (Polyrizon Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -25.1%, cap $26.1M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DRIO?
▼

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.03 (-0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (3)SEC (8)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
$16 Bull$3 Base$2 Bear
📬 FREE DRIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DRIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY DRIO SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 56.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$5.54-26.4% Next Q
Q2 (-2Q)
38
Grade E$4.08-14.7% Next Q
Q3 (-1Q)
36
Grade E$3.48-12.9% Next Q
Current
33
Grade E$3.03-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DRIO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DRIO currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.81) and Max Pain ($3.18) forces dealer call-delta covering toward $15.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DRIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DRIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
27.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $3$3.03H: $15
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on DRIO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 56.6% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like DRIO
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DRIO)

  • ✓Walkthrough of DRIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DRIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.33%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.31H $3.31L $3.00C $3.03VOL 55.5K
RES: $7.51SUP: $2.94SMA50: $5.81SMA200: $7.65
$11.49$9.19$6.89$4.59$2.29RES $7.51SUP $2.94$3.032026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DRIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DRIO Butterfly Map → + Track DRIO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DRIO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DRIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DRIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DRIO)

Health Care Rank #694 of 1015 ⚔️ BEAT vs DRIO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DRIO vs. BEAT, PLRZ, NEPH, TELA)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, DarioHealth Corp. (DRIO) ranks #694 by composite RQD confidence (33/100, grade E) and #801 by equity capitalization ($29.4M). Within this direct 5-issuer industry benchmark cohort, NEPH leads on earnings valuation at 29.8x trailing P/E, while NEPH leads on capital efficiency and profitability with 18.9% ROIC and 61.9% gross margin. NEPH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with DRIO at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DRIO ACTIVE
DarioHealth Corp.
E 33/100 — 56.6% -35.0% +1.00% $29.4M Benchmark Subject
BEAT
Heartbeam Inc.
D- 42/100 — — -35.0% -25.64% $31.0M /beat-vs-drio →
PLRZ
Polyrizon Ltd.
E 34/100 — — -25.1% +4.74% $26.1M /plrz-vs-drio →
NEPH
Nephros Inc.
C- 59/100 29.8x 61.9% 18.9% +2.21% $34.5M /neph-vs-drio →
TELA
TELA Bio Inc.
D- 35/100 — 67.7% -35.0% -1.33% $36.6M /tela-vs-drio →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533998 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DarioHealth Corp. (DRIO) reported GAAP revenue of $22.4M (-17.3% vs. FY2024 revenue of $27.0M , and -85.8% cumulative change since FY2023) , GAAP net income of -$41.7M, operating cash flow of -$25.9M, and free cash flow of -$26.1M (+32.6% YoY). On the balance sheet, DRIO closed FY2025 with $110.1M in total assets against $30.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $22.4M -$41.7M -$25.9M -$26.1M $110.1M $30.7M
FY2024 (FY) 2024-12-31 $27.0M -$42.7M -$38.6M -$38.7M $118.9M $23.5M
FY2023 (FY) 2023-12-31 $157.3M -$59.4M -$30.4M -$30.4M — —

3. DRIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DRIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, DarioHealth Corp. (NASDAQ: DRIO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $3.03 (+1.00% 1D, market cap $29.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, DRIO ranks #694 in composite RQD confidence.

How does DRIO compare to BEAT and PLRZ in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DRIO carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -35.0%. By comparison, BEAT (Heartbeam Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $31.0M) and PLRZ (Polyrizon Ltd.) posts a E grade (34/100 RQD, P/E N/A, ROIC -25.1%, cap $26.1M). Among the 5-stock peer group, NEPH leads on earnings multiple (29.8x) while NEPH leads on capital efficiency (18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DRIO?

Per DRIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533998), DarioHealth Corp. generated $22.4M in revenue (-17.3% YoY), -$41.7M in net income, and -$26.1M in free cash flow against $110.1M in total assets and $30.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DRIO trading relative to its 50-day, 200-day, and 52-week technical levels?

DRIO last traded at $3.03 (+1.00% on volume of 76,096 shares), positioning the stock -47.85% below its 50-day simple moving average ($5.81) and -60.39% below its 200-day simple moving average ($7.65). Across its 52-week range of $3.00 to $14.77, DRIO sits at the 0.3% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.65 to $3.41).

Direct Sub-Reports: DRIO RQD Cockpit DRIO 12M Forecast DRIO Earnings & Move DRIO Dividends & DRIP DRIO Insiders & 13F DRIO Whale Options DRIO Profit Sankey DRIO News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

DRIO — DarioHealth Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

DarioHealth Corp. (DRIO) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.03 (+1.00% 1D, market capitalization $29.4M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 56.6%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of 0.45x.

2. Business Model, Unit Margins & SEC Financial Trajectory

DarioHealth Corp. Is a NASDAQ-listed issuer classified in the Health Care sector and Medical/Dental Instruments industry. Reported revenue was $22.4M in FY 2025, . Gross margin is 56.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), DarioHealth Corp. (DRIO) reported $22.4M in annual revenue (up from $27.0M in FY2024, -17.3% YoY) and -$41.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($157.3M revenue, -$59.4M net income) through FY2025, DRIO scaled operating cash flow to -$25.9M and free cash flow to -$26.1M, backed by $110.1M in total assets against $30.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $3.00 – $14.77 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care sector and Medical/Dental Instruments industry classification. A prospective investor should note that the absence of mapped links means ripple effects from suppliers, customers, or peers cannot be assessed from the provided sources.

  • Key Question #1: Can DRIO sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $22.4M and free cash flow of -$26.1M, how will capital allocation balance growth reinvestment against $30.7M in total debt?
  • Key Question #3: How sensitive is DRIO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DRIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DarioHealth Corp. (DRIO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DRIO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DRIO Bull vs. Bear Conversation Board — What's Your Call at $3.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DRIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DRIO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $3.45 (+15.0%)
📌 Pinned Debate

BTIG initiated coverage with a Buy rating and $6 price target, implying upside from the $3.31 price.

BTIG initiated coverage with a Buy rating and $6 price target, implying upside from the $3.31 price.. When you look under the hood at DRIO, Fundamental Cash Engine is 9/20 with 56.6% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $14.77. My 12M target is $3.45.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (56.6%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $2.43 (-19.0%)
Spot @ $3.00

Reported operating losses of -$36.7M and FCF of -$26.1M in FY 2025 against cash of $21.8M signal near-term funding pressure.

Careful chasing DRIO at $3.00. Reported operating losses of -$36.7M and FCF of -$26.1M in FY 2025 against cash of $21.8M signal near-term funding pressure.. Gross margin is 56.6%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.43 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%